1092578-47-6 Usage
Description
3-((3S,4S)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile, also known as (3S,4S)-Tofacitinib, is an enantiopure stereoisomer of the drug Janus kinase 3 (Jak3) inhibitor (CP-690,550). It is a small molecule with a complex chemical structure that has been synthesized for its potential therapeutic applications.
Uses
Used in Pharmaceutical Industry:
3-((3S,4S)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile is used as a Janus kinase 3 (Jak3) inhibitor for the treatment of various autoimmune and inflammatory diseases. It works by inhibiting the activity of Jak3, a protein that plays a crucial role in the signaling pathways involved in these conditions.
Used in Research Applications:
In the field of research, 3-((3S,4S)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile is used as a valuable tool for studying the role of Jak3 in various biological processes and disease mechanisms. It helps researchers understand the molecular pathways and potential therapeutic targets for developing new treatments for autoimmune and inflammatory disorders.
Used in Drug Development:
3-((3S,4S)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile is also used in the development of new drugs targeting Jak3 and related pathways. Its enantiopure nature ensures that the desired stereoisomer is being studied, which is essential for the development of effective and safe medications.
Check Digit Verification of cas no
The CAS Registry Mumber 1092578-47-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,9,2,5,7 and 8 respectively; the second part has 2 digits, 4 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1092578-47:
(9*1)+(8*0)+(7*9)+(6*2)+(5*5)+(4*7)+(3*8)+(2*4)+(1*7)=176
176 % 10 = 6
So 1092578-47-6 is a valid CAS Registry Number.
1092578-47-6Relevant articles and documents
Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino) piperidin-1-yl)-3-oxopropanenitrile (CP-690,550)
Jiang, Jian-Kang,Ghoreschi, Kamran,Deflorian, Francesca,Chen, Zhi,Perreira, Melissa,Pesu, Marko,Smith, Jeremy,Nguyen, Dac-Trung,Liu, Eric H.,Leister, William,Costanzi, Stefano,O'Shea, John J.,Thomas, Craig J.
supporting information; experimental part, p. 8012 - 8018 (2009/12/07)
Here, we examine the significance that stereochemistry plays within the clinically relevant Janus kinase 3 (Jak3) inhibitor 1 (CP-690,550). A synthesis of all four enantiopure stereoisomers of the drug was carried out and an examination of each compound revealed that only the enantiopure 3R,4R isomer was capable of blocking Stat5 phosphorylation (Jak3 dependent). Each compound was profiled across a panel of over 350 kinases, which revealed a high level of selectivity for the Jak family kinases for these related compounds. Each stereoisomer retained a degree of binding to Jak3 and Jak2 and the 3R,4S and 3S,4R stereoisomers were further revealed to have binding affinity for selected members of the STE7 and STE20 subfamily of kinases. Finally, an appraisal of the minimum energy conformation of each stereoisomer and molecular docking at Jak3 was performed in an effort to better understand each compounds selectivity and potency profiles.
